tetano
Editor, Senior Moderator
Eur Respir J. 2010 Apr 22. [Epub ahead of print]
Factor V Leiden mutation does not affect coagulopathy or outcome in lethal H1N1 influenza.
Schouten M, van der Sluijs KF, Roelofs JJ, Levi M, van 't Veer C, van der Poll T.
Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; and Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Abstract
Influenza A is a major cause of mortality. Knowledge on coagulation activation in influenza infection is limited. The factor V Leiden (FVL) mutation is possibly subject to positive selection pressure. It is unknown whether this mutation impacts on the outcome of severe influenza. We here determined the effect of lethal influenza on pulmonary and systemic coagulation activation and determined whether FVL mutation alters coagulation activation in and the course of lethal influenza.Wild-type mice and mice heterozygous or homozygous for FVL were infected intranasally with a lethal dose of H1N1 influenza A. Mice were sacrificed after 48 or 96 hours for determination of coagulation activation, histopathology, pulmonary inflammatory parameters and viral loads or were observed in a survival study.Extensive local and systemic coagulation activation during lethal influenza was demonstrated by increased lung and plasma levels of thrombin-antithrombin complexes and fibrin degradation products and by pulmonary fibrin deposition. FVL mutation did not influence the procoagulant response, lung histopathology or survival. FVL mice demonstrated elevated viral loads 48 hours after infection.In conclusion, coagulation is activated locally and systemically during lethal murine influenza A infection. The FVL mutation does not influence coagulation activation, lung inflammation or survival in lethal influenza A.
PMID: 20413539 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20413539
Factor V Leiden mutation does not affect coagulopathy or outcome in lethal H1N1 influenza.
Schouten M, van der Sluijs KF, Roelofs JJ, Levi M, van 't Veer C, van der Poll T.
Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; and Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Abstract
Influenza A is a major cause of mortality. Knowledge on coagulation activation in influenza infection is limited. The factor V Leiden (FVL) mutation is possibly subject to positive selection pressure. It is unknown whether this mutation impacts on the outcome of severe influenza. We here determined the effect of lethal influenza on pulmonary and systemic coagulation activation and determined whether FVL mutation alters coagulation activation in and the course of lethal influenza.Wild-type mice and mice heterozygous or homozygous for FVL were infected intranasally with a lethal dose of H1N1 influenza A. Mice were sacrificed after 48 or 96 hours for determination of coagulation activation, histopathology, pulmonary inflammatory parameters and viral loads or were observed in a survival study.Extensive local and systemic coagulation activation during lethal influenza was demonstrated by increased lung and plasma levels of thrombin-antithrombin complexes and fibrin degradation products and by pulmonary fibrin deposition. FVL mutation did not influence the procoagulant response, lung histopathology or survival. FVL mice demonstrated elevated viral loads 48 hours after infection.In conclusion, coagulation is activated locally and systemically during lethal murine influenza A infection. The FVL mutation does not influence coagulation activation, lung inflammation or survival in lethal influenza A.
PMID: 20413539 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20413539